Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterised by elevated pulmonary arterial pressure and vascular resistance that eventually leads to right ventricular failure and death[1]
Early identification and intervention are key to changing the course of the disease[2]
PAH is a severe and often fatal complication of CTD:[3]
PAH is a leading cause of death in patients with SSc, accounting for >50% of deaths in SSc-PAH patients[6]
Adapted from Badesch et al. 2010[7]
Component not published? componentType is undefined.
Medical Scientific Liaison Pulmonary
Hypertension NL
+31 6 1238 17 11
mkruk1@its.jnj.com
Medical Advisor Pulmonary
Hypertension NL
+31 6 53 72 73 03
rjansse9@its.jnj.com
Hebt u een vraag voor ons of niet gevonden wat u zoekt? Neem contact op, wij helpen u graag verder.
Ontdek hier het Janssen portfolio en de bijbehorende SmPC's.
Ontdek interactieve 3D-animaties van de menselijke anatomie en verschillende ziektebeelden.
ALT, alanine aminotransferase; AST, aspartate aminotransferase;CHD, congenital heart disease; CI, confidence interval; CTD, connective tissue disease; ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ESC, European Society of Cardiology; HIV, human immunodeficiency virus; HPAH, heritable pulmonary arterial hypertension; HR, hazard ratio; IPAH, idiopathic pulmonary arterial hypertension; LFT, liver function test; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PoPH, portopulmonary hypertension; RHC, right heart catheterisation; SSc, systemic sclerosis; TRV, tricuspid regurgitation velocity; ULN, upper limit of normal; 6MWD, six-minute walk distance